<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924699</url>
  </required_header>
  <id_info>
    <org_study_id>MRG002-004</org_study_id>
    <nct_id>NCT04924699</nct_id>
  </id_info>
  <brief_title>A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer.</brief_title>
  <official_title>A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Miracogen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Miracogen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety, efficacy, pharmacokinetics, and&#xD;
      immunogenicity of MRG002 in patients with HER2-positive unresectable locally advanced or&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) by Independent Review Committee (IRC)</measure>
    <time_frame>Baseline to study completion (up to12 months)</time_frame>
    <description>ORR is defined as the proportion of subjects with complete response (CR) and partial response (PR) assessed by Independent Review Committee (IRC) according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by Investigator</measure>
    <time_frame>Baseline to study completion (up to 12 months)</time_frame>
    <description>ORR is defined as the proportion of subjects with CR and PR assessed by investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline to study completion (up to 12 months)</time_frame>
    <description>DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline to study completion (up to 12 months)</time_frame>
    <description>TTR is defined as the duration from the start of treatment to the first onset of CR or PR in tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline to study completion (up to 12 months)</time_frame>
    <description>DCR is defined as the proportion of subjects achieving CR, PR, and stable disease (SD) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to study completion (up to 12 months)</time_frame>
    <description>PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to study completion (up to 12 months)</time_frame>
    <description>OS is defined as the duration from the start of treatment to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment</time_frame>
    <description>Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration-time curve</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment</time_frame>
    <description>Plot of drug concentration changing with time after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
    <description>The proportion of patients with positive ADA immunogenicity results.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MRG002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRG002</intervention_name>
    <description>Administrated intravenously</description>
    <arm_group_label>MRG002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Aged 18 to 75 (including 18 and 75)，both genders;&#xD;
&#xD;
             2. Expected survival time ≥ 6 months;&#xD;
&#xD;
             3. The score of ECOG for performance status is 0 or 1;&#xD;
&#xD;
             4. Patients with histologically and/or cytologically confirmed HER2-positive invasive&#xD;
             breast cancer, including unresectable locally advanced breast cancer (LABC) or&#xD;
             metastatic breast cancer (MBC);&#xD;
&#xD;
             5. Failed in the prior trastuzumab ± pertuzumab and taxane therapy with&#xD;
             advanced/metastatic disease, or progression within 12 months after new adjuvant or&#xD;
             adjuvant therapy; or those who have failed in the prior TKI and/or HER2-ADC therapy&#xD;
             can also be enrolled;&#xD;
&#xD;
             6. Patients must have imaging evidence of tumor progression during or after the most&#xD;
             recent treatment confirmed by the investigator and at least one measurable lesion&#xD;
             baseline according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.1);&#xD;
&#xD;
             7. Organ functions must meet the basic requirements;&#xD;
&#xD;
             8. Willing to sign the ICF and follow the requirements specified in the protocol;&#xD;
             Reproductive male and female subjects of childbearing age shall be willing to take&#xD;
             effective contraceptive measures from the date of signing the ICF to 6 months after&#xD;
             the last dose; Women of childbearing potential must have a negative pregnancy test&#xD;
             within 7 days before the first dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of other primary malignancies;&#xD;
&#xD;
             2. Received other study drugs for clinical trials, any anti-tumor drugs/ biological or&#xD;
             investigational therapeutic drug, radiotherapy, anti-tumor vaccine therapy, etc.,&#xD;
             within 4 weeks prior to the first dose;&#xD;
&#xD;
             3. Presence of central nervous system (CNS) metastasis;&#xD;
&#xD;
             4. The pleural or peritoneal effusion with combined clinical symptoms, which seriously&#xD;
             endangers the life safety of the subjects or urgently needs clinical treatment. Or the&#xD;
             pericardial effusion with combined clinical symptoms;&#xD;
&#xD;
             5. Any severe or uncontrolled systemic disease, uncontrolled heart disease,&#xD;
             uncontrolled diabetes, and active bleeding signs judged by the investigator;&#xD;
&#xD;
             6. Evidence of active infection, including hepatitis B, hepatitis C or human&#xD;
             immunodeficiency virus (HIV) infection, active bacteria infection requiring systematic&#xD;
             anti-infective therapy, infection caused by other viruses, fungi, rickettsia or&#xD;
             parasites;&#xD;
&#xD;
             7. History of hypersensitivity to any component of MRG002 or history of&#xD;
             hypersensitivity of ≥ Grade 3 to trastuzumab injection;&#xD;
&#xD;
             8. Subjects with active autoimmune disease or a history of autoimmune disease are&#xD;
             receiving immunosuppressive agents or systemic hormone therapy, and are still&#xD;
             receiving within 2 weeks prior to enrollment;&#xD;
&#xD;
             9. History of interstitial pneumonia, severe chronic obstructive pulmonary disease,&#xD;
             severe pulmonary insufficiency, symptomatic bronchospasm, etc;&#xD;
&#xD;
             10. Other conditions inappropriate for participation in this study, as deemed by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fifth Medical Center of PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunjinang Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Fourth Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Program Director</last_name>
    <phone>86-21-61637960</phone>
    <email>clinicaltrials@miracogen.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zefei Jiang, Doctor</last_name>
      <phone>13901372170</phone>
      <email>jiangzefei@csco.cog.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunjiang Liu, Doctor</last_name>
      <phone>13703297890</phone>
      <email>Lyj818326@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRG002</keyword>
  <keyword>Antibody Drug Conjugate (ADC)</keyword>
  <keyword>HER2</keyword>
  <keyword>Breast Cancer (BC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

